Awareness around the potential opportunities created by artificial intelligence has never been higher, but pharma’s biggest challenge in 2019 will be adopting and scaling the right technology to improve patient outcomes, says an industry executive.
The more outsourcing experience a pharma company has, the less important its proximity to contract manufacturing partners becomes, outlines Novo Nordisk VP.
Eli Lilly and Company and AC Immune have signed an agreement for the research and development of tau aggregation inhibitor small molecules, and AC Immune signed a strategic partnership with WuXi biologics.
Most CROs are struggling with employee retention, a challenge not new to the industry, which has seen turnover levels at or above 20% for seven of the last 10 years, according to a recent report.
By Jim Kremidas, executive director, Association of Clinical Research Professionals
This time next year, I hope I can write a column with the headline “2019: The year of cooperation and communication in the clinical trial industry.” We’ve made some exciting progress toward that end in 2018. Now it’s time to take it to the next level.
The Indian government seeks to boost local drug production by stipulating that the ‘local content’ of domestic products is 75% and 10% for those that are non-domestic.
The biopharma industry is on the precipice of making personalized medicine a reality with access to massive amounts of data, computing power, and artificial intelligence to run in silico clinical trials, says GNS Healthcare CEO.
Almac announced it has increased its supply of neo-antigen peptides for individualized cancer treatments with the addition of another stream of GMP manufacturing.